Quhill, F., & Beiderbeck, A. (2017). Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema. Global and Regional Health Technology Assessment, 4(1), 155–164. https://doi.org/10.33393/grhta.2017.391